Clients in the media Clients IN the MEDIA

Ensuring your story is visible.
Fierce-Pharma

Valneva’s not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales

Valneva has yet to successfully usher its inactivated COVID-19 vaccine across the regulatory finish line, but analysts still see reason to bet on the French vaccine specialist.

Fierce-Biotech

Stellanova, a ‘new star’ in the biotech constellation, hopes for bright future with $15.5M series A

The Houston-based preclinical biotech has raised a $15.5 million series A round led by Sporos Bioventures. The funding will go toward bringing Stellanova’s lead antibody into the clinic, building out a discovery platform and growing the team, including leadership hires later this year.

Fierce-Pharma

Scynexis clinches FDA green light for vaginal yeast infection blockbuster-to-be

The FDA this week approved Scynexis’ ibrexafungerp tablets, now christened Brexafemme, to treat vaginal yeast infections. The green light marks the first approval in a new class of antifungal drugs in more than 20 years and propels Scynexis into the commercial realm with a potential blockbuster in tow.

biospace

Calliditas is Getting to the Heart of Berger’s Disease

But this orphan disease is one of the main reasons the team at Calliditas Therapeutics goes to work every day.

CEO Of Rain Therapeutics On The Company’s Developments In Cancer Treatment

Rain Therapeutics (RAIN) is a clinical-stage precision oncology company. They recently went public in 2021. Co-founder and CEO, Avanish Vellanki, speaks about Rain Therapeutics’ internal growth potential as well as the effect that its new treatment Rain-32 will have. Vellanki states that Rain-32 has been seen to triple or quadruple the survival time of patients with difficult to treat cancer. Rain Therapeutics is continuing to build a pipeline of targeted cancer therapies. Tune in to find out more.

Biotech CEOs weigh in on post-Covid changes to the industry

At Fountain, specifically, recent advances in AI have enabled us to spearhead a new unbiased approach to drug discovery and development.  We are using this platform to discover, refine, and advance a pipeline of disease-modifying therapies for age-related diseases, addressing both novel compounds and targets.

Why You Shouldn’t Rely on a COVID-19 Antibody Test to Determine Immunity

“However, the mere presence of antibodies to a virus does not necessarily mean an individual has protective immunity to reinfection,” Ian Chan, CEO of Boston-based biotech developer Abpro, told Healthline.

Fierce-Biotech

ASCO: Boehringer, OSE offer promising glimpse of the immuno-oncology drug at the heart of their $1.4B deal

When Boehringer Ingelheim and OSE Immunotherapeutics teamed up in 2018 to develop OSE’s first-in-class checkpoint inhibitor, it was clear BI had high hopes for the immuno-oncology asset: The closely held German company paid about $18 million upfront but then piled on royalties and milestones, making the deal worth $1.4 billion to OSE.